Hims & Hers Health vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 40)
Hims & Hers Health logo

Hims & Hers Health

EmergingHealthcare

General

Telehealth platform with $872M 2024 revenue; GLP-1 weight loss, hair, and sexual health prescriptions shipped directly to 2M+ subscribers; went public via SPAC merger in 2021;

AI VisibilityBeta
Overall Score
C40
Category Rank
#362 of 596
AI Consensus
85%
Trend
stable
Per Platform
ChatGPT
40
Perplexity
34
Gemini
40

About

Hims & Hers Health is a telehealth and wellness platform offering personalized treatment plans and prescription medications for conditions including hair loss, erectile dysfunction, weight management, skincare, and mental health. Founded in 2017 and headquartered in San Francisco, Hims & Hers went public via SPAC merger in January 2021 and has grown into a $1B+ revenue publicly traded health company. The platform connects patients with licensed providers asynchronously and ships prescription treatments directly to homes, eliminating the friction of in-person doctor visits for lifestyle health conditions.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

40
Overall Score
90
#362
Category Rank
#2
85
AI Consensus
83
stable
Trend
stable
40
ChatGPT
92
34
Perplexity
93
40
Gemini
89
37
Claude
96
37
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
company
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.